Fig. 7

LCN2 is a target of H3K18 lactylation and acts as an oncogene. a CUT&Tag was performed with H3K18la antibodies in T24 cells. H3K18la could be enriched in the promoter region of numerous genes. b KEGG database analysis was carried out in H3K18la-related genes. c Transcriptome sequencing was performed in control and circXRN2-overexpressing T24 and TCCSUP cells. d Flow diagram confirming the downstream target of H3K18la. e H3K18la peaks in the promoter regions of LCN2, NRARP and KRT80. f LCN2 mRNA and protein levels were measured in circXRN2-overexpressing cells. g Different concentrations of 2-DG and oxamate were added to T24 and TCCSUP cells, and LCN2 protein levels were measured by immunoblotting. h LCN2 mRNA was upregulated in bladder cancer and was closely related to the overall survival time of bladder cancer patients in the TCGA database and K‒M plotter. i Primers targeting different fragments of the LCN2 gene are indicated, and the c, d, and e sites are H3K18la peaks of the LCN2 promoter region in CUT&Tag. j ChIP assay following qPCR was used to detect the binding status of H3K18la in the LCN2 promoter region in bladder cancer cells treated with or without glycolysis inhibitors. k-n The roles of LCN2 in cell proliferation and migration were verified by CCK-8 assay, colony formation assay, Transwell migration assay and wound healing assay. All the data are presented as the mean ± standard deviation (n = 3). *P < 0.05, **P < 0.01, compared with the control group